# US 2025/0188103 A1 · Heterocyclic glp-1 agonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0188103 A1
- Document ID: US20250188103A1
- Status: Published application
- Kind: A1
- Application number: 18/845,381
- Filed: 2023-03-08
- Published: 2025-06-12
- Earliest claimed: 2022-03-09
- Assignees: Gasherbrum Bio, Inc.
- Applicants: Gasherbrum Bio, Inc.
- Inventors: Xichen LIN; Qinghua MENG; Weiqiang XING; Zhongmiao XU
- Web page: https://patentgrep.com/patent/US20250188103A1

## CPC

- C07D 487/14: Ortho-condensed systems
- C07F 9/6561: containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C07D 273/02: having two nitrogen atoms and only one oxygen atom
- C07D 307/80: Radicals substituted by oxygen atoms
- C07D 309/04: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 333/72: Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
- C07D 471/04: Ortho-condensed systems
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

This disclosure relates to GLP-1 agonists, pharmaceutical compositions, and methods of use thereof.

## Claims

### Claim 1

A compound of Formula I:
or a pharmaceutically acceptable salt, deuterated analog, or solvate thereof, wherein:
X is C and Y is N, or Y is C and X is N and the dashed lines represent an optional bond such that the moiety
is
where bond y is attached to Y and bond x is attached to X;
Ring A is C6-10 aryl, C5-10 cycloalkyl, 5-10 membered heterocyclyl, or 5-10 membered heteroaryl, each of which is optionally substituted with from 1-5 substituents each independently selected from the group consisting of halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, and C3-6 cycloalkyl;
R1, R2, and R3 are each independently selected from the group consisting of H and C1-6 alkyl which is optionally substituted with from 1-6 substituents each independently selected from the group consisting of halo, —OH, and C1-6 alkoxy;
L1 is selected from the group consisting of —C(═O)—, —CH2—, —CH(C1-6 alkyl)-, and —S(═O)2;
Ring B is selected from the group consisting of
wherein bb represents point of attachment to L1;
R4, R5, R6, and R7 are independently selected from the group consisting of H, halo, and C1-6 alkyl;
L3 is a bond or C1-3 alkylene;
L4 is a bond or C1-5 alkylene;
R8a and R8b are independently selected from the group consisting of H and C1-6 alkyl optionally substituted with one or more substituents independently selected from the group consisting of halo and C3-15 cycloalkyl;
or R8a and R8b taken together with the carbon atom to which each is attached forms a C3-15 cycloalkyl ring which is optionally substituted with from 1-3 independently selected C1-6 alkyl, wherein the C1-6 alkyl is optionally substituted with from 1-6 independently selected from Rf;
or the moiety -L3-C(R8aR8b)-L4-R9 is a phenyl substituted with C(═O)OH, and optionally 1-4 additional substituents independently selected from Rf;
R9 is selected from the group consisting of C(═O)OH, C(═O)(OC1-6 alkyl), C(═O)NR9aR9b, (IX-1), (IX-2), (IX-3), and (IX-4):
R9a is H or C1-6 alkyl;
R9b is H, C1-6 alkyl, C(═O)(C1-6 alkyl), S(O)0-2(C1-6 alkyl), or cyano;
R9c, R9d, R9e, R9f, and R9g are each independently selected from the group consisting of H, C1-6 alkyl optionally substituted with from 1-6 independently selected halo and C1-6 alkoxy, and C(═O)(C1-6 alkyl);
Ring C is selected from the group consisting of 3-12 membered heterocyclyl, C3-15 cycloalkyl, and 5-10 membered heteroaryl, each of which is optionally substituted with from 1-3 RCa;
each RCa is independently selected from the group consisting of halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, and NRcRd;
or a pair of RCa on the same or different ring atoms, taken together with the ring atom(s) to which each is attached, forms a carbocyclic ring including from 3-8 ring atoms;
L2 is selected from the group consisting of
wherein aa represents the point of attachment to Q;
n1 is an integer from 1-3;
L2A is a bond or C1-10 alkylene;
RLa is selected from the group consisting of H, C1-6 alkyl, and C(═O)(C1-6 alkyl);
each of RLb and RLc is independently selected from the group consisting of H and C1-6 alkyl;
Q is selected from the group consisting of C1-10 alkyl; C3-15 cycloalkyl; 3-12 membered heterocyclyl; 5-10 membered heteroaryl; and C6-10 aryl, wherein Q is substituted with —P(═O)RaRb, and optionally substituted with from 1-6 additional substituents independently selected from RQ;
each RQ is independently selected from the group consisting of
(a) halo;
(b) cyano;
(c) OH or oxo;
(d) —NRcRd;
(e) —C(═O)NRcRd or —S(O)2NRcRd;
(f) —S(═O)0-2Re;
(g) C1-6 alkyl optionally substituted with from 1-6 independently selected Rf;
(h) C1-6 alkoxy optionally substituted with from 1-6 independently selected Rf;
(i) 3-12 membered heterocyclyl optionally substituted with from 1-6 independently selected Rg;
(j) C6-10 aryl optionally substituted with from 1-6 independently selected Rg;
(k) 5-10 membered heteroaryl optionally substituted with from 1-6 independently selected Rg;
(l) C3-8 cycloalkyl optionally substituted with from 1-6 independently selected Rg;
(in) —P(═O)RaRb; and
(n) —(CRhRh)q1—S(O)2-Le-Re, wherein q1 is 1, 2, or 3;
or Q is C3-15 cycloalkyl; 3-12 membered heterocyclyl; 5-10 membered heteroaryl; and C6-10 aryl, each of which is optionally substituted with from 1-6 substituents each independently selected from the group consisting of RQA and RQB;
provided that one or both of (aa) or (bb) applies:
(aa) Q is substituted with at least one RQB; or
(bb) Q is 4-12 membered heterocyclyl or 7-10 membered bicyclic heteroaryl, wherein Q comprises an endocyclic S(O)2 group;
each RQA is independently selected from the group consisting of
(a) halo;
(b) cyano;
(c) OH or oxo;
(d) —NRaRb;
(e) —C(═O)NRcRd;
(f) C1-6 alkyl optionally substituted with from 1-6 independently selected Rf;
(g) C1-6 alkoxy optionally substituted with from 1-6 independently selected Rf;
(h) 3-12 membered heterocyclyl optionally substituted with from 1-6 independently selected Rg;
(i) C6-10 aryl optionally substituted with from 1-6 independently selected Rg;
(j) 5-10 membered heteroaryl optionally substituted with from 1-6 independently selected Rg; and
(k) C3-8 cycloalkyl optionally substituted with from 1-6 independently selected Rg;
each RQB is independently selected from the group consisting of:
(a) -La-S(O)2-Lb-Re; and
(b) 4-12 membered heterocyclyl or 7-10 membered bicyclic heteroaryl, each of which comprises an endocyclic S(O)2 group, wherein the heterocyclyl or heteroaryl is optionally substituted with from 1-6 independently selected Rg;
La is selected from the group consisting of —N(H)—, —N(Rc)—, and —(CRhRh)q1;
Lb is selected from the group consisting of —O—, —N(H)—, —N(Rc)—, and —(CRhRh)q2—;
q1 and q2 are independently 0, 1, 2, 3, or 4;
provided that when La is —(CRhRh)q1— and q1 is 0, then -Lb-Re is other than unsubstituted C1-3 alkyl;
Ra and Rb are independently selected from the group consisting of C1-6 alkyl which is optionally substituted with from 1-6 substituents each independently selected from the group consisting of C1-6 alkoxy, C3-6 cycloalkyl, and halo; C3-6 cycloalkyl optionally substituted with from 1-3 substituents each independently selected from the group consisting of C1-3 alkyl and halo; and C6-10 aryl optionally substituted with from 1-3 independently selected C1-3 alkyl; or
Ra and Rb taken together with the phosphorous atom to which each is attached forms a ring including from 5-8 ring atoms, wherein from 0-2 ring atoms (in addition to the phosphorous attached to Ra and Rb) are heteroatoms each independently selected from the group consisting of O, S, and N, wherein the ring is optionally substituted with from 1-3 independently selected C1-6 alkyl;
each Rc and Rd are independently selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl, C(═O)(C1-6 alkyl), C(═O)(C3-6 cycloalkyl), C(═O)O(C1-6 alkyl), S(O)1-2(C1-6 alkyl), and S(O)1-2(C3-6 cycloalkyl), wherein the C1-6 alkyl, C(═O)(C1-6 alkyl), C(═O)(C3-6 cycloalkyl), C(═O)O(C1-6 alkyl), S(O)1-2(C1-3alkyl), and S(O)1-2(C3-6 cycloalkyl) are each optionally substituted with from 1-6 substituents independently selected from the group consisting of —OH, halo, and C1-6 alkoxy;
Re is H, or Rc is selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-6 cycloalkyl, and 3-8 membered heterocyclyl, each of which is optionally substituted with from 1-3 substituents each independently selected from the group consisting of halo, cyano, C1-3 alkyl, C1-3 haloalkyl, —OH, NH2, NH(C1-3 alkyl), N(C1-3 alkyl)2, C1-3 alkoxy, and C1-3 haloalkoxy;
Le is a bond, NRc, or O;
each Rf is independently selected from the group consisting of halo, —OH, NRcRd, C1-6 alkoxy, C1-6 haloalkoxy, and 3-12 membered heterocyclyl which is optionally substituted with from 1-4 substituents each independently selected from the group consisting of —OH, C1-6 alkyl, and 3-12 membered heterocyclyl;
each Rg is independently selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, NRcRd, cyano, halo, C3-6 cycloalkyl, and 3 to 12 membered heterocyclyl optionally substituted with one or more substituents each independently selected from the group consisting of C1-6 alkyl and C(═O)C1-6 alkyl; and
each occurrence of Rh is independently selected from the group consisting of H, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, and halo; or
a pair of Rh on the same or different carbon atom(s), taken together with the carbon atom(s) connecting them forms C3-6 cycloalkyl or 4-8 membered heterocyclyl, each of which is optionally substituted with from 1-3 substituents each independently selected from the group consisting of halo, cyano, C1-3 alkyl, C1-3 haloalkyl, —OH, C1-3 alkoxy, and C1-3 haloalkoxy.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the moiety
is
where bond y is attached to Y and bond x is attached to X.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the moiety
is
where bond y is attached to Y and bond x is attached to X.

### Claim 4

A compound of Formula II:
or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein:
Q1, Q2, Q3, Q4, and Q5 are defined according to (AA) or (BB) below:
(AA)
Q1 and Q5 are independently selected from the group consisting of N, CH, and CRQC;
Q2, Q3, and Q4 are independently selected from the group consisting of N, CH, CRQC, and CRQD, provided that at least one of Q2, Q3, and Q4 is CRQD;
each is a single bond or double bond, provided that the ring including Q1-Q5 is aromatic;
(BB)
Q1 is a bond;
Q2, Q3, Q4, and Q5 are independently selected from the group consisting of O, S, N, NH, NRc, CH, CRQC, and CRQD, provided that at least one of Q2, Q3, Q4, and Q5 is CRQD;
each is a single bond or double bond, provided that the ring including Q1-Q5 is aromatic;
RQD is P(═O)RaRb, wherein Ra and Rb are independently selected from the group consisting of C1-6 alkyl which is optionally substituted with from 1-6 substituents each independently selected from the group consisting of C1-6 alkoxy, C3-6 cycloalkyl, and halo; C3-6 cycloalkyl optionally substituted with from 1-3 substituents each independently selected from the group consisting of C1-3 alkyl and halo; and C6-10 aryl optionally substituted with from 1-3 independently selected C1-3 alkyl; or
Ra and Rb taken together with the phosphorous atom to which each is attached forms a ring including from 5-8 ring atoms, wherein from 0-2 ring atoms (in addition to the phosphorous attached to Ra and Rb) are heteroatoms each independently selected from the group consisting of O, S, and N, wherein the ring is optionally substituted with from 1-3 independently selected C1-6 alkyl;
each RQC is independently selected from the group consisting of (a) halo; (b) cyano; (c) OH; (d) —NRcRd; (e) C(═O)NRcRd; (f) S(═O)0-2Re; (g) C1-6 alkyl optionally substituted with from 1-6 independently selected Rf; (h) C1-6 alkoxy optionally substituted with from 1-6 substituents each independently selected from the group consisting of hydroxy, halo, and C1-6 alkoxy; (i) 3-12 membered heterocyclyl optionally substituted with one or more substituents each independently selected from the group consisting of C1-6 alkyl and C(═O)(C1-6 alkyl); (j) C6-10 aryl optionally substituted with from 1-3 independently selected C(═O)(C1-6 alkyl); and (k) 5-10 membered heteroaryl optionally substituted with from 1-6 independently selected Rg;
or a pair of RQC on adjacent carbon atoms, taken together with the atom to which each is attached, forms a ring including from 5-8 ring atoms, wherein from 0-2 ring atoms are heteroatoms each independently selected from the group consisting of O, N, and S, wherein said ring is optionally substituted with from 1-2 independently selected R groups;
L2 is selected from the group consisting of
wherein aa represents the point of attachment to the ring containing Q1-Q5;
n1 is an integer from 1-3;
L2A is a bond or C1-10 alkylene;
RLa is selected from the group consisting of H, C1-6 alkyl, and C(═O)(C1-6 alkyl);
each of RLb and RLC is independently selected from the group consisting of H and C1-6 alkyl;
Ring A is C6-10 aryl, C5-7 cycloalkyl, 5-7 membered heterocyclyl, or 5-10 membered heteroaryl, each of which is optionally substituted with from 1-5 substituents each independently selected from the group consisting of halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, and C3-6 cycloalkyl;
R1, R2, and R3 are each independently selected from the group consisting of H and C1-6 alkyl which is optionally substituted with from 1-6 substituents each independently selected from the group consisting of halo, —OH, and C1-6 alkoxy;
L1 is selected from the group consisting of —C(═O)—, —CH2—, —CH(C1-6 alkyl)-, and —S(═O)2;
Ring B is selected from the group consisting of
wherein bb represents point of attachment to L1;
R4, R5, R6, and R7 are independently selected from the group consisting of H, halo, and C1-6 alkyl;
L3 is a bond or C1-3 alkylene;
L4 is a bond or C1-5 alkylene;
R8a and R8b are independently selected from the group consisting of H and C1-6 alkyl optionally substituted with one or more substituents independently selected from the group consisting of halo and C3-15 cycloalkyl; or
R8a and R8b taken together with the carbon atom to which each is attached forms a C3-15 cycloalkyl ring which is optionally substituted with from 1-3 independently selected C1-6 alkyl, wherein the C1-6 alkyl is optionally substituted with from 1-6 independently selected Rf;
R9 is selected from the group consisting of C(═O)OH, C(═O)(OC1-6 alkyl), C(═O)NR9aR9b, (IX-1), (IX-2), (IX-3), and (IX-4):
R9a is H or C1-6 alkyl;
R9b is H, C1-6 alkyl, C(═O)(C1-6 alkyl), S(O)0-2(C1-6 alkyl), or cyano;
R9c, R9d, R9e, R9f, and R9g are each independently selected from the group consisting of H;
C1-6 alkyl optionally substituted with from 1-6 independently selected halo and C1-6 alkoxy; and C(═O)(C1-6 alkyl);
Ring C is selected from the group consisting of 3-12 membered heterocyclyl; C3-15 cycloalkyl; and 5-10 membered heteroaryl, each of which is optionally substituted with from 1-3 RCa;
each RCa is independently selected from the group consisting of halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, and NRcRd;
or a pair of RCa on the same or different ring atoms, taken together with the ring atom(s) to which each is attached, forms a carbocyclic ring including from 3-8 ring atoms;
each Rc and Rd are independently selected from the group consisting of H, C1-6 alkyl, C(═O)(C1-6 alkyl), C(═O)(C3-6 cycloalkyl), C(═O)O(C1-6 alkyl), S(O)1-2(C1-6 alkyl), and S(O)1-2(C3-6 cycloalkyl), wherein the C1-6 alkyl, C(═O)(C1-6 alkyl), C(═O)(C3-6 cycloalkyl), C(═O)O(C1-6 alkyl), S(O)1-2(C1-6 alkyl), and S(O)1-2(C3-6 cycloalkyl) are each optionally substituted with from 1-6 substituents independently selected from the group consisting of —OH, halo, and C1-6 alkoxy;
Rc is H, C1-6 alkyl, or C1-6 haloalkyl;
each Rf is independently selected from the group consisting of halo, —OH, NRcRd, C1-6 alkoxy, C1-6 haloalkoxy, and 3-12 membered heterocyclyl which is optionally substituted with from 1-4 substituents each independently selected from the group consisting of —OH, C1-6 alkyl, and 3-12 membered heterocyclyl;
each Rg is independently selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, NRcRd, and 3 to 12 membered heterocyclyl optionally substituted with one or more substituents each independently selected from the group consisting of C1-6 alkyl and C(═O)C1-6 alkyl; and
each Rh is independently selected from the group consisting of halo, cyano, C1-6 alkyl, C1-6 haloalkyl, —OH, NH2, NH(C1-3 alkyl), N(C1-3 alkyl)2, C1-3 alkoxy, and C1-3 haloalkoxy.

### Claim 5

A compound of Formula III:
or a pharmaceutically acceptable salt, deuterated analog, or solvate thereof, wherein:
Ring D is selected from the group consisting of C3-15 cycloalkyl; 3-12 membered heterocyclyl; 5-10 membered heteroaryl; and C6-10 aryl, each of which is optionally substituted with from 1-6 substituents each independently selected from the group consisting of RQA and RQB;
provided that one or both of (aa) or (bb) applies:
(aa) Ring D is substituted with at least one RQB; or
(bb) Ring D is 4-12 membered heterocyclyl or 7-10 membered bicyclic heteroaryl, wherein Ring D comprises an endocyclic S(O)2 group;
each RQA is independently selected from the group consisting of
(a) halo;
(b) cyano;
(c) OH or oxo;
(d) —NRaRb;
(e) —C(═O)NRcRd;
(f) C1-6 alkyl optionally substituted with from 1-6 independently selected Rf;
(g) C1-6 alkoxy optionally substituted with from 1-6 independently selected Rf;
(h) 3-12 membered heterocyclyl optionally substituted with from 1-6 independently selected Rg;
(i) C6-10 aryl optionally substituted with from 1-6 independently selected Rg;
(j) 5-10 membered heteroaryl optionally substituted with from 1-6 independently selected Rg; and
(k) C3-8 cycloalkyl optionally substituted with from 1-6 independently selected Rg;
each RQB is independently selected from the group consisting of
(a) -La-S(O)2-Lb-Re; and
(b) 4-12 membered heterocyclyl or 7-10 membered bicyclic heteroaryl, each of which comprises an endocyclic S(O)2 group, wherein the heterocyclyl or heteroaryl is optionally substituted with from 1-6 independently selected Rg;
La is selected from the group consisting of —N(H)—, —N(Rc)—, and —(CRhRh)q1;
Lb is selected from the group consisting of —O—, —N(H)—, —N(Rc)—, and —(CRhRh)q2—;
q1 and q2 are independently 0, 1, 2, 3, or 4;
provided that when La is —(CRhRh)q1— and q1 is 0, then -Lb-Re is other than unsubstituted C1-3 alkyl;
L2 is selected from the group consisting of
wherein aa represents the point of attachment to Ring D;
n1 is an integer from 1-3;
L2A is a bond or C1-10 alkylene;
RLa is selected from the group consisting of H, C1-6 alkyl, and C(═O)(C1-6 alkyl);
each of RLb and RLc is independently selected from the group consisting of H and C1-6 alkyl;
Ring A is C6-10 aryl, C5-10 cycloalkyl, 5-10 membered heterocyclyl, or 5-10 membered heteroaryl, each of which is optionally substituted with from 1-5 substituents each independently selected from the group consisting of halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, and C3-6 cycloalkyl;
R1, R2, and R3 are each independently selected from the group consisting of H and C1-6 alkyl which is optionally substituted with from 1-6 substituents each independently selected from the group consisting of halo, —OH, and C1-6 alkoxy;
L1 is selected from the group consisting of —C(═O)—, —CH2—, —CH(C1-6 alkyl)-, and —S(═O)2;
Ring B is selected from the group consisting of
wherein bb represents point of attachment to L1;
R4, R5, R6, and R7 are independently selected from the group consisting of H, halo, and C1-6 alkyl;
L3 is a bond or C1-3 alkylene;
L4 is a bond or C1-5 alkylene;
R8a and R8b are independently selected from the group consisting of H and C1-6 alkyl optionally substituted with one or more substituents independently selected from the group consisting of halo and C3-15 cycloalkyl; or
R8a and R8b taken together with the carbon atom to which each is attached forms a C3-15 cycloalkyl ring which is optionally substituted with from 1-3 independently selected C1-6 alkyl, wherein the C1-6 alkyl is optionally substituted with from 1-6 independently selected Rf;
R9 is selected from the group consisting of C(═O)OH, C(═O)(OC1-6 alkyl), C(═O)NR9aR9b(IX-1), (IX-2), (IX-3), and (IX-4):
R9a is H or C1-6 alkyl;
R9b is H, C1-6 alkyl, C(═O)(C1-6 alkyl), S(O)0-2(C1-6 alkyl), or cyano;
R9c, R9d, R9e, R9f, and R9g are each independently selected from the group consisting of H; C1-6 alkyl optionally substituted with from 1-6 independently selected halo and C1-6 alkoxy; and C(═O)(C1-6 alkyl);
Ring C is selected from the group consisting of 3-12 membered heterocyclyl; C3-15 cycloalkyl; and 5-10 membered heteroaryl, each of which is optionally substituted with from 1-3 RCa;
each RCa is independently selected from the group consisting of halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, and NRcRd;
or a pair of RCa on the same or different ring atoms, taken together with the ring atom(s) to which each is attached, forms a carbocyclic ring including from 3-8 ring atoms;
each Ra and Rb are independently selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl, C(═O)(C1-6 alkyl), C(═O)(C3-6 cycloalkyl), and C(═O)O(C1-6 alkyl), wherein the C1-6 alkyl, C3-6 cycloalkyl, C(═O)(C1-6 alkyl), C(═O)(C3-6 cycloalkyl), and C(═O)O(C1-6 alkyl) are each optionally substituted with from 1-6 substituents independently selected from the group consisting of —OH, halo, and C1-6 alkoxy;
each Rc and Rd are independently selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl, C(═O)(C1-6 alkyl), C(═O)(C3-6 cycloalkyl), C(═O)O(C1-6 alkyl), S(O)1-2(C1-6 alkyl), and S(O)1-2(C3-6 cycloalkyl), wherein the C1-6 alkyl, C3-6 cycloalkyl, C(═O)(C1-6 alkyl), C(═O)(C3-6 cycloalkyl), C(═O)O(C1-6 alkyl), S(O)1-2(C1-6 alkyl), and S(O)1-2(C3-6 cycloalkyl) are each optionally substituted with from 1-6 substituents independently selected from the group consisting of —OH, halo, and C1-6 alkoxy;
Re is H, or Re is selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-6 cycloalkyl, and 3-8 membered heterocyclyl, each of which is optionally substituted with from 1-3 substituents each independently selected from the group consisting of halo, cyano, C1-3 alkyl, C1-3 haloalkyl, —OH, NH2, NH(C1-3 alkyl), N(C1-3 alkyl)2, C1-3 alkoxy, and C1-3 haloalkoxy;
each Rf is independently selected from the group consisting of halo, —OH, NRcRd, C1-6 alkoxy, C1-6 haloalkoxy, and 3-12 membered heterocyclyl which is optionally substituted with from 1-4 substituents each independently selected from the group consisting of —OH, C1-6 alkyl, and 3-12 membered heterocyclyl;
each Rg is independently selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, NRcRd, cyano, halo, C3-6 cycloalkyl, and 3 to 12 membered heterocyclyl optionally substituted with one or more substituents each independently selected from the group consisting of C1-6 alkyl and C(═O)C1-6 alkyl; and
each occurrence of Rh is independently selected from the group consisting of H, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, and halo; or
a pair of Rh on the same or different carbon atom(s), taken together with the carbon atom(s) connecting them forms C3-6 cycloalkyl or 4-8 membered heterocyclyl, each of which is optionally substituted with from 1-3 substituents each independently selected from the group consisting of halo, cyano, C1-3 alkyl, C1-3 haloalkyl, —OH, C1-3 alkoxy, and C1-3 haloalkoxy.

### Claim 6

A compound of Formula IV:
or a pharmaceutically acceptable salt, deuterated analog, or solvate thereof, wherein:
Ring A is C6-10 aryl, C5-10 cycloalkyl, 5-10 membered heterocyclyl, or 5-10 membered heteroaryl, each of which is optionally substituted with from 1-5 substituents each independently selected from the group consisting of halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, and C3-6 cycloalkyl;
R1, R2, and R3 are each independently selected from the group consisting of H and C1-6 alkyl which is optionally substituted with from 1-6 substituents each independently selected from the group consisting of halo, —OH, and C1-6 alkoxy;
L1 is selected from the group consisting of —C(═O)—, —CH2—, —CH(C1-6 alkyl)-, and —S(═O)2;
Ring B is selected from the group consisting of
wherein bb represents point of attachment to L1;
R4, R5, R6, and R7 are independently selected from the group consisting of H, halo, and C1-6 alkyl;
L3 is a bond or C1-3 alkylene;
L4 is a bond or C1-5 alkylene;
R8a and R8b are independently selected from the group consisting of H and C1-6 alkyl optionally substituted with one or more substituents independently selected from the group consisting of halo and C3-15 cycloalkyl; or
R8a and R8b taken together with the carbon atom to which each is attached forms a C3-15 cycloalkyl ring which is optionally substituted with from 1-3 independently selected C1-6 alkyl, wherein the C1-6 alkyl is optionally substituted with from 1-6 independently selected Rf;
R9 is selected from the group consisting of C(═O)OH, C(═O)(OC1-6 alkyl), C(═O)NR9aR9b, (IX-1), (IX-2), (IX-3), and (IX-4):
R9a is H or C1-6 alkyl;
R9b is H, C1-6 alkyl, C(═O)(C1-6 alkyl), S(O)0-2(C1-6 alkyl), or cyano;
R9c, R9d, R9e, R9f, and R9g are each independently selected from the group consisting of H; C1-6 alkyl optionally substituted with from 1-6 independently selected halo and C1-6 alkoxy; and C(═O)(C1-6 alkyl);
Ring C is selected from the group consisting of 3-12 membered heterocyclyl; C3-10 cycloalkyl; and 5-10 membered heteroaryl, each of which is optionally substituted with from 1-3 RCa;
each RCa is independently selected from the group consisting of halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, and NRcRd;
or a pair of RCa on the same or different ring atoms, taken together with the ring atom(s) to which each is attached, forms a carbocyclic ring including from 3-8 ring atoms;
L2 is selected from the group consisting of
wherein aa represents the point of attachment to Q;
n1 is an integer from 1-3;
L2A is a bond or C1-10 alkylene;
RLa is selected from the group consisting of H, C1-6 alkyl, and C(═O)(C1-6 alkyl);
each of RLb and RLc is independently selected from the group consisting of H and C1-6 alkyl;
Q is selected from the group consisting of C1-10 alkyl; C3-15 cycloalkyl; 3-12 membered heterocyclyl; 5-10 membered heteroaryl; and C6-10 aryl, each of which is optionally substituted with from 1-6 independently selected RQ;
each RQ is independently selected from the group consisting of
(a) halo;
(b) cyano;
(c) OH or oxo;
(d) —NRcRd;
(e) —C(═O)NRcRd or —S(O)2NRcRd;
(f) —S(═O)0-2Re;
(g) C1-6 alkyl optionally substituted with from 1-6 independently selected Rf;
(h) C1-6 alkoxy optionally substituted with from 1-6 independently selected Rf;
(i) 3-12 membered heterocyclyl optionally substituted with from 1-6 independently selected Rg;
(j) C6-10 aryl optionally substituted with from 1-6 independently selected Rg;
(k) 5-10 membered heteroaryl optionally substituted with from 1-6 independently selected Rg;
(l) C3-8 cycloalkyl optionally substituted with from 1-6 independently selected Rg;
(m) P(═O)RaRb; and
(n) —(CRhRh)qS(O)2-Le-Re, wherein q1 is 1, 2, or 3;
Ra and Rb are independently selected from the group consisting of C1-6 alkyl which is optionally substituted with from 1-6 substituents each independently selected from the group consisting of C1-6 alkoxy, C3-6 cycloalkyl, and halo; C3-6 cycloalkyl optionally substituted with from 1-3 substituents each independently selected from the group consisting of C1-3 alkyl and halo; and C6-10 aryl optionally substituted with from 1-3 independently selected C1-3 alkyl; or
Ra and Rb taken together with the phosphorous atom to which each is attached forms a ring including from 5-8 ring atoms, wherein from 0-2 ring atoms (in addition to the phosphorous attached to Ra and Rb) are heteroatoms each independently selected from the group consisting of O, S, and N, wherein the ring is optionally substituted with from 1-3 independently selected C1-6 alkyl;
each Rc and Rd are independently selected from the group consisting of H, C1-6 alkyl, C3-6 cycloalkyl, C(═O)(C1-6 alkyl), C(═O)(C3-6 cycloalkyl), C(═O)O(C1-6 alkyl), S(O)1-2(C1-6 alkyl), and S(O)1-2(C3-6 cycloalkyl), wherein the C1-6 alkyl, C(═O)(C1-6 alkyl), C(═O)(C3-6 cycloalkyl), C(═O)O(C1-6 alkyl), S(O)1-2(C1-6 alkyl), and S(O)1-2(C3-6 cycloalkyl) are each optionally substituted with from 1-6 substituents independently selected from the group consisting of —OH, halo, and C1-6 alkoxy;
Re is H, or Re is selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C3-6 cycloalkyl, and 3-8 membered heterocyclyl, each of which is optionally substituted with from 1-3 substituents each independently selected from the group consisting of halo, cyano, C1-3 alkyl, C1-3 haloalkyl, —OH, NH2, NH(C1-3 alkyl), N(C1-3 alkyl)2, C1-3 alkoxy, and C1-3 haloalkoxy;
Le is a bond, NRc, or O;
each Rf is independently selected from the group consisting of halo, —OH, NRcRd, C1-6 alkoxy, C1-6 haloalkoxy, and 3-12 membered heterocyclyl which is optionally substituted with from 1-4 substituents each independently selected from the group consisting of —OH, C1-6 alkyl, and 3-12 membered heterocyclyl;
each Rg is independently selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, NRcRd, cyano, halo, C3-6 cycloalkyl, and 3 to 12 membered heterocyclyl optionally substituted with one or more substituents each independently selected from the group consisting of C1-6 alkyl and C(═O)C1-6 alkyl; and
each occurrence of Rh is independently selected from the group consisting of H, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, and halo; or
a pair of Rh on the same or different carbon atom(s), taken together with the carbon atom(s) connecting them forms C3-6 cycloalkyl or 4-8 membered heterocyclyl, each of which is optionally substituted with from 1-3 substituents each independently selected from the group consisting of halo, cyano, C1-3 alkyl, C1-3 haloalkyl, —OH, C1-3 alkoxy, and C1-3 haloalkoxy.

### Claim 7 (depends on 1)

The compound of claim 1, wherein Ring A is C6-10 aryl, optionally substituted with from 1-5 substituents each independently selected from the group consisting of halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, and C3-6 cycloalkyl.

### Claim 8 (depends on 1)

The compound of claim 1, wherein Ring A is phenyl, optionally substituted with from 1-3 substituents each independently selected from the group consisting of fluoro, methyl, and cyclopropyl.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R1 and R2 are H.

### Claim 10 (depends on 1)

The compound of claim 1, wherein R3 is C1-6 alkyl.

### Claim 11 (depends on 1)

The compound of claim 1, wherein R3 is methyl.

### Claim 12 (depends on 1)

The compound of claim 1, wherein L1 is —C(═O)—.

### Claim 13 (depends on 1)

The compound of claim 1, wherein Ring B is:

### Claim 14 (depends on 1)

The compound of claim 1, wherein Ring B is:

### Claim 15 (depends on 1)

The compound of claim 1, wherein Ring B is:

### Claim 16 (depends on 1)

The compound of claim 1, wherein Ring B is:

### Claim 17 (depends on 1)

The compound of claim 1, wherein R4, R5, R6, and R7 are H.

### Claim 18 (depends on 1)

The compound of claim 1, wherein L3 is a bond.

### Claim 19 (depends on 1)

The compound of claim 1, wherein R8a and R8b together with the carbon atom to which each is attached form a C3-15 cycloalkyl.

### Claim 20 (depends on 1)

The compound of claim 1, wherein R8a and R8b together with the carbon atom to which each is attached form a cyclopropyl.

### Claim 21 (depends on 1)

The compound of claim 1, wherein R9 is

### Claim 22 (depends on 1)

The compound of claim 1, wherein R9d is H.

### Claim 23 (depends on 1)

The compound of claim 1, wherein Ring C is 3-12 membered heterocyclyl.

### Claim 24 (depends on 1)

The compound of claim 1, wherein Ring C is tetrahydropyranyl.

### Claim 25 (depends on 1)

The compound of claim 1, wherein L2 is
wherein aa represents the point of attachment to Q.

### Claim 26 (depends on 1)

The compound of claim 1, wherein L2A is a bond.

### Claim 27

A compound of Formula IIE:
or a pharmaceutically acceptable salt, deuterated analog, or solvate thereof, wherein:
Ring B is selected from the group consisting of:
wherein bb represents the point of attachment to the —C(O)— and xx represents the point of attachment to Xb;
R4, R5, R6, and R7 are independently selected from the group consisting of H, halo, and C1-6 alkyl;
RAA, RAB, and RAC are each independently hydrogen, halo, C1-3 alkyl, or C3-6 cycloalkyl;
R3 is H or C1-3 alkyl;
RQC is H or halo;
RQD is selected from the group consisting of: (a) H; (b) —NH2; (c) —NH(C1-3 alkyl); (d) halo; (e) C1-3 alkoxy optionally substituted with from 1-3 independently selected halo; and (f) C1-3 alkyl optionally substituted with from 1-3 independently selected halo;
Ra and Rb are each independently selected from the group consisting of: C1-4 alkyl and C3-6 cycloalkyl; or
Ra and Rb taken together with the phosphorous atom to which each is attached form a ring including from 5-8 ring atoms, wherein from 0-1 ring atom (in addition to the phosphorous attached to Ra and Rb) is a heteroatom independently selected from the group consisting of: O, S, and N;
R8c is H or C1-3 alkyl;
XB is CH or N; and
each RCb is independently selected from the group consisting of H and C1-3 alkyl.

### Claim 28

A compound selected from:
or a pharmaceutically acceptable salt, deuterated analog, or solvate thereof.

### Claim 29 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt, deuterated analog, or solvate thereof, and a pharmaceutically acceptable excipient.

### Claim 30 (depends on 1)

A method for treating a GLP-1 associated disease, disorder, or condition, the method comprising administering to a patient in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, deuterated analog, or solvate thereof.

### Claim 31 (depends on 30)

The method of claim 30, wherein the disease, disorder, or condition is selected from the group consisting of type 1 diabetes mellitus, type 2 diabetes mellitus, early onset type 2 diabetes mellitus, idiopathic type 1 diabetes mellitus (Type 1b), youth-onset atypical diabetes (YOAD), maturity onset diabetes of the young (MODY), latent autoimmune diabetes in adults (LADA), obesity (including hypothalamic obesity and monogenic obesity), weight gain from use of other agents, idiopathic intracranial hypertension, Wolfram syndrome, gout, excessive sugar craving, hypertriglyceridemia, dyslipidemia, malnutrition-related diabetes, gestational diabetes, kidney disease, adipocyte dysfunction, sleep apnea, visceral adipose deposition, eating disorders, cardiovascular disease, congestive heart failure, myocardial infarction, left ventricular hypertrophy, peripheral arterial disease, stroke, hemorrhagic stroke, ischemic stroke, transient ischemic attacks, atherosclerotic cardiovascular disease, traumatic brain injury, peripheral vascular disease, endothelial dysfunction, impaired vascular compliance, vascular restenosis, thrombosis, hypertension, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, hyperglycemia, post-prandial lipemia, metabolic acidosis, ketosis, hyperinsulinemia, impaired glucose metabolism, insulin resistance, hepatic insulin resistance, alcohol use disorder, chronic renal failure, metabolic syndrome, syndrome X, smoking cessation, premenstrual syndrome, angina pectoris, diabetic nephropathy, impaired glucose tolerance, diabetic neuropathy, diabetic retinopathy, macular degeneration, cataract, glomerulosclerosis, arthritis, osteoporosis, treatment of addiction, cocaine dependence, bipolar disorder/major depressive disorder, skin and connective tissue disorders, foot ulcerations, psoriasis, primary polydipsia, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), ulcerative colitis, inflammatory bowel disease, colitis, irritable bowel syndrome, Crohn's disease, short bowel syndrome, Parkinson's, Alzheimer's disease, impaired cognition, schizophrenia, Polycystic Ovary Syndrome (PCOS), or any combination thereof.

### Claim 32 (depends on 1)

A method of treating type 2 diabetes mellitus in a patient in need thereof, the method comprising administering to a patient in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, deuterated analog, or solvate thereof.

### Claim 33 (depends on 1)

A method for modulating insulin levels in a patient in need of such modulating, the method comprising administering to a patient in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, deuterated analog, or solvate thereof.

### Claim 34 (depends on 1)

A method for modulating glucose levels in a patient in need of such modulating, the method comprising administering to a patient in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, deuterated analog, or solvate thereof.

### Claim 35 (depends on 30)

The method of claim 30, further comprising administering an additional therapy or therapeutic agent to the patient.

### Claim 36 (depends on 35)

The method of claim 35, wherein the additional therapy or therapeutic agent is selected from the group consisting of an anti-diabetic agent, an anti-obesity agent, a GLP-1 receptor agonist, an anti-emetic agent, an agent to treat non-alcoholic steatohepatitis (NASH), gastric electrical stimulation, dietary monitoring, physical activity, or a combination thereof.
